Ovarian epithelial cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ovarian epithelial cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Olaparib and Bevacizumab for Maintenance Treatment in Patients with HRD-Positive Ovarian Cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-olaparib-and-bevacizumab-for-maintenance-treatment-in-patients-with-hrd-positive-ovarian-cancer/ Wed, 29 Apr 2026 14:24:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-olaparib-and-bevacizumab-for-maintenance-treatment-in-patients-with-hrd-positive-ovarian-cancer/ This clinical trial is focused on studying the effectiveness of a treatment for patients with advanced, high-grade epithelial ovarian cancer, including cancer of the fallopian tube or primary peritoneal cancer. The study involves patients whose tumors show a specific genetic defect in a DNA repair mechanism known as homologous recombination deficiency (HRD). The treatment being tested combines two medications: olaparib, which is a type of drug known as a PARP inhibitor, and bevacizumab, a monoclonal antibody. These medications are given as maintenance therapy, which means they are used to help keep the cancer from coming back after the initial treatment.

The purpose of the study is to confirm how well this combination works in patients who have already received a standard chemotherapy treatment that includes a platinum-based drug and bevacizumab. After completing this initial treatment, patients who show a complete or partial response and have HRD-positive tumors will start taking olaparib along with bevacizumab. The study will observe how patients respond to this maintenance therapy over time.

Participants in the trial will receive the treatment over a period of time, and their health will be monitored to see how the cancer responds and to check for any side effects. The study aims to provide more information about the effectiveness and safety of using olaparib and bevacizumab together in treating this type of cancer. The trial will also gather data on the characteristics of patients who benefit from this treatment approach.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>